NeuroQuest has developed NeuroScreen™, a novel blood-based diagnostic test for Alzheimer's disease (AD). The technology is based on the specific response of the immune system to a amyloid-beta accumulation. The company's propriety technology is based on the award-winning research of Professor Michal Schwartz of the Weizmann Institute of Science. NeuroQuest has licensed the intellectual property covering this technology from Yeda (the Technology Transfer Company of the Weizmann Institute of Science) and holds an exclusive global license for its development and commercialization.
NeuroQuest has established a US subsidiary and clinical development center in Charleston, South Carolina with the assistance and financial support of the South Carolina Research Authority (SCRA). They are working with Vikor Scientific, a CLIA-certified lab, to provide the data required for FDA approval, and with Pentara Corporation for data analysis.